Abstract
e17543Background: Gynecologic cancers account for approximately 18% of all female cancers. Since management options for advanced gynecologic cancers are limited, immune checkpoint blockade is a pot...
Highlights
Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including cancer of the cervix, ovaries, uterus, fallopian tubes, vagina and vulva
According to the 2014 WHO Classification of Tumors of the Female Reproductive Organs[27, 60] (51.28%) cases were serous adenocarcinoma including 2 cases with minor clear cell adenocarcinoma components, of which 59 cases occurred in the ovary and 1 case was endometrial; 3 (2.56%) cases were clear cell adenocarcinoma in the ovary; 17 (14.53%) cases were endometrioid adenocarcinoma, of which one case occurred in the ovary whereas the remainder were endometrial; 31 (26.5%) cases were squamous cell carcinoma in the cervix; 1 (0.85%) case was mucinous adenocarcinoma in the cervix; and 5 (4.27%) cases were of other histologic types in the ovary, including one case with osteosarcoma, one case with immature teratoma, one case with sex cord-mesenchymal tumor, and two cases with dysgerminoma
To the best of our knowledge, the present study is the first to assess tumor mutational burden (TMB) in Chinese patients with gynecologic cancers and to describe the mutational profiles that are associated with an increased TMB
Summary
Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including cancer of the cervix, ovaries, uterus, fallopian tubes, vagina and vulva. The overall five-year relative survival rate for cervical cancer is 45.4% in China[5]. Endometrial cancer was estimated to account for 63.4 thousand new cancer cases in 20154. The overall five-year relative survival rate for endometrial cancer is 55.1% in China[5]. The overall five-year relative survival rate for ovarian cancer is 38.9% in China[5]. The five-year relative survival rates of ovarian cancer were 90.2%, 68.3%, 32.9%, and 16.1% for stage I, II, III, and IV, respectively, according to data from a historical cohort study in Hong Kong[6]; the data at the national level are still not available. We characterized and identified specific genes associated with an increased TMB in Chinese patients with gynecologic cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
